Cited by 1,415Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCutaneous Melanoma Detection and Management

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

Weber, Jeffrey S., Kähler, Katharina C., Hauschild, Axel·2012·Journal of Clinical Oncology

DOI 10.1200/jco.2012.41.6750

Open this paper in CoChat — free account

Abstract

Monoclonal antibodies directed against the immune checkpoint protein cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152)—ipilimumab and tremelimumab—have been investigated in metastatic melanoma and other cancers and have shown promising results. Recently, ipilimumab was approved by the US Food and Drug Administration for the treatment of metastatic melanoma. We review the literature on managing the adverse effects and kinetics of tumor regression with ipilimumab and provide guidelines on their management. During treatment with these antibodies, a unique set of adverse effects may occur, called immune-related adverse events (irAEs). These include rashes, which may rarely progress to life-threatening toxic epidermal necrolysis, and colitis, characterized by a mild to moderate, but occasionally also severe and persistent diarrhea. Hypophysitis, hepatitis, pancreatitis, iridocyclitis, lymphadenopathy, neuropathies, and nephritis have also been reported with ipilimumab. Early recognition of irAEs and initiation of treatment are critical to reduce the risk of sequelae. Interestingly, irAEs correlated with treatment response in some studies. Unique kinetics of response have been observed with CTLA-4 blockade with at least four patterns: (1) response in baseline lesions by week 12, with no new lesions seen; (2) stable disease, followed by a slow, steady decline in total tumor burden; (3) regression of tumor after initial increase in total tumor burden; and (4) reduction in total tumor burden during or after the appearance of new lesion(s) after week 12. We provide a detailed description of irAEs and recommendations for practicing oncologists who are managing them, along with the unusual kinetics of response associated with ipilimumab therapy.

Integrity signals

Registry

Crossref · 10.1200/jco.2012.41.6750

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citation
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citation
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Self-citation
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
The B7 family revisited
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Cancer regression and autoimmunity induced by cytotoxic t lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006

Flagged first, then by citations

Show all 33 references

Research works printed but not linked: 5

Lebbé C, Presented at Perspectives in Melanoma XII, Scheveningen/the Hague, the Netherlands
Weber JS, 2009, J Clin Oncol, 27, 466s
Saenger YM, 2008, Cancer Immun, 8, 1
Pennock GK, 2011, Am J Clin Oncol
Yuan J, 2010, Cancer Immun, 10, 1

Sorted by citations

Items 801–900 of 999

Sargramostim and Immune Checkpoint Inhibitors: Combinatorial Therapeutic Studies in Metastatic Melanoma
Tarhini, A. A., Joshi, I., & Garner, F. (2021) · Immunotherapy · doi:10.2217/imt-2021-0119 · Cited by 17
Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not)
Corsello, S. M., Salvatori, R., Barnabei, A., Vecchis, L. D., Marchetti, P., & Torino, F. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2213-y · Cited by 17
Toxicités dermatologiques des inhibiteurs de checkpoint immunologiques
Sibaud, V., Boulinguez, S., Pagès, C., Riffaud, L., Lamant, L., Chira, C., Boyrie, S., Vigarios, É., Tournier, É., & Meyer, N. (2018) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2018.01.047 · Cited by 17
Photosensitivity and cancer immune‐targeted therapies
Lembo, S., Raimondo, A., Conti, V., & Venturini, M. (2020) · Photodermatology Photoimmunology & Photomedicine · doi:10.1111/phpp.12533 · Cited by 17
Candidate approaches for predicting vitiligo recurrence: an effective model and biomarkers
Liu, B., Shen, J., Li, J., Tian, B., Zhou, B., Gui, J., Li, Z., Zhang, Y., Hu, W., & Li, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1468665 · Cited by 16
Strategies to mitigate the toxicity of cancer therapeutics
Kahn, A. M., Blenman, K., Sonis, S. T., & Lustberg, M. B. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2022.02.006 · Cited by 16
Tumor-infiltrating lymphocytes as a prognostic and predictive factor for Melanoma
Vargas, G. M., Shafique, N., Xu, X., & Karakousis, G. C. (2024) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2024.2312102 · Cited by 16
“Even so, irAEs associated with immune checkpoint inhibitors for the treat-ment of melanoma have a range from mild rashes and colitis to life-threatening toxic epidermal necrolysis and fulminant myocarditis [98,99].”
Background
Developing melanoma therapeutics: overview and update
Korman, J. B., & Fisher, D. E. (2013) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1210 · Cited by 16
Antigen Selection for Enhanced Affinity T-Cell Receptor–Based Cancer Therapies
Hickman, E. S., Lomax, M. E., & Jakobsen, B. K. (2016) · SLAS DISCOVERY · doi:10.1177/1087057116637837 · Cited by 16
Intralesional and systemic immunotherapy for metastatic melanoma
Luu, C., Khushalani, N. I., & Zager, J. S. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1233961 · Cited by 16
“while in other cases, cessation of therapy is an effective last resort if other measures fail [5].”
Background
Predicting Durable Responses to Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Using a Multi-Feature Model
Wang, L., Zhang, H., Pan, C., Yi, J., Cui, X., Li, N., Wang, J., Gao, Z., Wu, D., Chen, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.829634 · Cited by 16
Side Effects and Toxicities of Targeted Therapies in Stage IV Melanoma
Ascierto, P. A., Bastholt, L., Hersey, P., Cinat, G., Eggermont, A. M. M., Hauschild, A., Espinosa, E., & Robert, C. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3182a39858 · Cited by 16
Self-citation
Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients
Rogiers, A., van den Oord, J. J., Garmyn, M., Stas, M., Kenis, C., Wildiers, H. P. M. W., Marine, J., & Wolter, P. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0304-7 · Cited by 16
Management of skin adverse events associated with immune checkpoint inhibitors in patients with melanoma
Thebeau, M. S., Rubin, K. M., Hofmann, M., Grimm, J., Weinstein, A., & Choi, J. N. (2017) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12458 · Cited by 16
Immune Checkpoint Inhibitors Renal Side Effects and Management
Rassy, E., Kourié, H. R., Rizkallah, J. J., Karak, F. E., Hanna, C., Chelala, D. N., & Ghosn, M. G. (2016) · Immunotherapy · doi:10.2217/imt-2016-0099 · Cited by 16
Ultrasound-Mediated Microbubble Destruction Suppresses Melanoma Tumor Growth
Jang, K. W., Seol, D., Ding, L., Lim, T. H., Frank, J. A., & Martin, J. A. (2018) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2017.12.011 · Cited by 16
US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm
Lacouture, M. E., Choi, J. N., Ho, A. Y., Leventhal, J. S., McLellan, B. N., Andriessen, A., Sauder, M. B., & Mitchell, E. (2021) · Journal of Drugs in Dermatology · doi:10.36849/jdd.6229 · Cited by 15
Case Report: Ipilimumab‐induced Multisystem Autoimmune‐like Toxicities Suggestive of Vogt‐Koyanagi‐Harada–like Syndrome
Monferrer-Adsuara, C., Bel, L. H., Hernández-Garfella, M. L., Remolí-Sargues, L., Ortiz-Salvador, M., Castro-Navarro, V., & Cervera-Taulet, E. (2021) · Optometry and Vision Science · doi:10.1097/opx.0000000000001798 · Cited by 15
Ipilimumab-induced autoimmune hypophysitis: a differential for sellar mass lesions
Rodrigues, B. T., Otty, Z. A., Sangla, K. S., & Shenoy, V. V. (2014) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-14-0098 · Cited by 15
Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer
Heigener, D., & Reck, M. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.957187 · Cited by 15
Immune Checkpoint Therapy in Non–Small Cell Lung Cancer
Marrone, K. A., & Brahmer, J. R. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000178 · Cited by 15
Hypokalemic Paralysis Secondary to Immune Checkpoint Inhibitor Therapy
Balakrishna, P., & Villegas, A. E. (2017) · Case Reports in Oncological Medicine · doi:10.1155/2017/5063405 · Cited by 15
“)e mainstay of immune-related adverse event (irAE) management is immune suppression, including high-dose steroids, immunosuppressants, and potentially TNF-α inhibitors [16].”
Vaccine protection against SIVmac239 acquisition
Martins, M. A., Bischof, G., Shin, Y. C., Lauer, W. A., Gonzalez-Nieto, L., Watkins, D. I., Rakasz, E. G., Lifson, J. D., & Desrosiers, R. C. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814584116 · Cited by 15
“However, because systemic IC blockade can be associated with immune adverse effects (29), vaccine strategies will need to be optimized to safely harness the potent immunostimulatory effects of IC modulation.”
Background
Application and Prospects of Molecular Imaging in Immunotherapy
Wang, W., Gao, Z., Wang, L., Li, J., Yu, J., Han, S., & Meng, X. (2020) · Cancer Management and Research · doi:10.2147/cmar.s269773 · Cited by 15
Efectos adversos inmunomediados gastrointestinales y hepáticos inducidos por los inhibidores del punto de control inmunitario: estudio descriptivo observacional
Sanz-Segura, P., Cámara, P. G., Bonilla, E. M. F., Arbonés-Mainar, J. M., & Monterde, V. B. (2020) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2020.07.009 · Cited by 15
Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development
Cheng, K., Wang, Y., Zhou, Y., Xia, R., Tang, L., & Liu, J. (2021) · Clinical Medicine Insights Oncology · doi:10.1177/11795549211056261 · Cited by 15
Immunotherapeutic Approaches for Glioblastoma Treatment
Yaghi, N. K., & Gilbert, M. R. (2022) · Biomedicines · doi:10.3390/biomedicines10020427 · Cited by 16
“In addition to the most common symptoms, diarrhea and enterocolitis, potentially requiring ICU admission, nonspecific symptoms, such as weakness, fatigue, confusion, and nausea, can lead to the diagnosis of complex hormonal disorders involving the thyroid and pituitary glands [84,85].”
Background
Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab
Graziani, G., Lisi, L., Tentori, L., & Navarra, P. (2022) · Experientia supplementum · doi:10.1007/978-3-030-91311-3_10 · Cited by 16
Skin manifestations associated with checkpoint inhibitors
Nazzaro, G., Buffon, S., Giacalone, S., Maronese, C. A., & Marzano, A. V. (2022) · JEADV Clinical Practice · doi:10.1002/jvc2.27 · Cited by 15
Prevention and Treatment of Side Effects of Immunotherapy for Bladder Cancer
Lou, K., Feng, S., Zhang, G., Zou, J., & Zou, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.879391 · Cited by 16
“Ipilimumab Ipilimumab, originally developed by Bristol-Meyers Squibb as an anti-CTLA-4 monoclonal antibody for the treatment of melanoma, is also used in combination with nivolumab for the treatment of advanced kidney cancer and different types of metastatic colorectal cancer (79), with common side effects including t…”
Background
The management of immune-related adverse events associated with immune checkpoint blockade
Fay, A. P., Moreira, R. B., Filho, P. R. S. N., Albuquerque, C., & Barrios, C. H. (2016) · Expert Review of Quality of Life in Cancer Care · doi:10.1080/23809000.2016.1142827 · Cited by 15
“5% of patients receiving anti-CTLA-4 antibodies [40].”
Case Report of Ipilimumab-Induced Diffuse, Nonnecrotizing Granulomatous Lymphadenitis and Granulomatous Vasculitis
Arellano, K., Mosley, J. C., & Moore, D. C. (2017) · Journal of Pharmacy Practice · doi:10.1177/0897190017699762 · Cited by 15
Modulating T-cell-based cancer immunotherapy via particulate systems
Truong, D. H., Tran, T. T. P., Nguyen, H. T., Phung, C. D., Pham, T. T., Yong, C. S., Kim, J. O., & Tran, T. H. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1474360 · Cited by 15
“Unfortunately, only a small fraction of patients benefited from these therapies, and significant immune-related toxicities still need to be reduced for better patient compliance [85,86].”
Background
Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper
Silvestris, N., Argentiero, A., Beretta, G. D., Bartolo, P. D., Montagnani, M., Danesi, R., Ferrari, P., D’Oronzo, S., Gori, S., Russo, A. D., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103066 · Cited by 16
Clinical deployment of antibodies for treatment of melanoma
Curti, B. D., & Urba, W. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.025 · Cited by 14
Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities
Furudate, S., Fujimura, T., Kambayashi, Y., Hidaka, T., Hashimoto, A., & Aiba, S. (2016) · Case Reports in Oncology · doi:10.1159/000450974 · Cited by 14
Hepatobiliary and Pancreatic Adverse Events
Zhang, H. C., Wang, L. S., & Miller, E. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-79308-1_13 · Cited by 14
Development of a Hybrid-Imaging-Based Prognostic Index for Metastasized-Melanoma Patients in Whole-Body 18F-FDG PET/CT and PET/MRI Data
Küstner, T., Vogel, J., Hepp, T., Forschner, A., Pfannenberg, C., Schmidt, H., Schwenzer, N. F., Nikolaou, K., la Fougère, C. J., & Seith, F. (2022) · Diagnostics · doi:10.3390/diagnostics12092102 · Cited by 14
“Besides tremendous treatment success in advanced melanoma patients, the rapid development of oncologic treatment options comes with increasingly high costs [54] and can cause severe life-threatening side effects [55].”
Background
Advancements in colorectal cancer immunotherapy: from CAR-T cells to exosome-based therapies
Arabi, S., Fadaee, M., Kazemi, T., & Rahmani, M. R. (2025) · Journal of drug targeting · doi:10.1080/1061186x.2024.2449482 · Cited by 16
“Some of the most common irAes include colitis, pneumonitis, hepatitis, endocrinopathies, and dermatitis [43,44]. these toxicities arise due to the activation of the immune system against normal tissues, a consequence of the non-specific nature of some immunothera-peutic agents.”
Targeting the immune system to treat lung cancer: rationale and clinical experience
Guibert, N. M., Delaunay, M., & Mazières, J. (2015) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465815578349 · Cited by 14
Systemic Treatment of Cutaneous Adverse Events after Immune Checkpoint Inhibitor Therapy: A Review
Brown, A. M., Masterson, W. M., Lo, J., & Patel, A. B. (2021) · Dermatitis · doi:10.1097/der.0000000000000776 · Cited by 14
Acute Liver Failure following a Single Dose of Atezolizumab, as Assessed for Causality Using the Updated RUCAM
Tzadok, R., Levy, S., Aouizerate, J., & Shibolet, O. (2022) · Case Reports in Gastrointestinal Medicine · doi:10.1155/2022/5090200 · Cited by 14
“Hepatic side effects have been reported in 3–10% of patients with ICI [12, 13] and most commonly manifest as asymptomatic elevations of liver enzymes, mostly transaminases, and mildly elevated bilirubin [14].”
Background
Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer
Issa, M., Tang, J., Guo, Y., Coss, C. C., Mace, T. A., Bischof, J. J., Phelps, M. A., Presley, C. J., & Owen, D. H. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2094772 · Cited by 14
“the timing and relevance of biomarker testing problematic [130].”
Immune checkpoint inhibitor-induced hypophysitis: clinical and biochemical features
Esteves-Ferreira, S., & Rosinha, P. M. O. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04659-5 · Cited by 14
The Essential Role of Circulating Thyroglobulin in Maintaining Dominance of Natural Regulatory T Cell Function to Prevent Autoimmune Thyroiditis
Brown, N. K., Morris, G. P., Flynn, J. C., & Kong, Y. M. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0035-1548872 · Cited by 15
Regulatory Mechanisms and Therapeutic Targeting of PD-L1 Trafficking and Stability in Cancer Immunotherapy
Mani, M., Park, J. W., & Martin, T. F. J. (2025) · Cancers · doi:10.3390/cancers17111747 · Cited by 16
“The incidence and severity of these irAEs can vary depending on the specific agent used, with combination regimens (e.g., anti-CTLA-4 plus anti-PD-1) showing significantly higher rates of grade ≥ 3 toxicities compared to monotherapy [40].”
Drug-Induced Liver Injury due to Biologics and Immune Check Point Inhibitors
Bessone, F., & Bjornsson, E. S. (2023) · Medical Clinics of North America · doi:10.1016/j.mcna.2022.12.008 · Cited by 15
Risk Factors of Venous Thromboembolic Disease in Cancer Patients Treated with Immune Checkpoint Inhibitor
le Sève, J. D., Guédon, A. F., Bordenave, S., Agard, C., Connault, J., Pistorius, M., Quereux, G., & Espitia, O. (2023) · Thrombosis and Haemostasis · doi:10.1055/s-0043-1769609 · Cited by 13
Immune Checkpoint Inhibitor-Induced Pancreatic Injury: Clinical and Radiological Profile and Response to Steroids
Thomas, A. S., Abreo, M., Ahmed, A. S., Manikonda, S. P. R., Eyada, M., Issac, A. G., Abraham, F. O., Jacob, J. S., Wang, Y., Yedururi, S., et al. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.11.020 · Cited by 13
Real-world incidences and risk factors of immune-related adverse events in patients treated with immune checkpoint inhibitors: A nationwide retrospective cohort study
Kim, Y. J., Lee, M., Kim, E. H., Lee, S., Park, S., Hong, M. H., Shin, S. J., Jung, I., Lee, C., & Lee, C. S. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216998 · Cited by 14
New therapeutic options in systemic treatment of advanced cutaneous melanoma
Mackiewicz-Wysocka, M., Żołnierek, J., & Wysocki, P. J. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.748032 · Cited by 13
Treatment Algorithms in Stage IV Melanoma
Espinosa, E., Grob, J., Dummer, R., Rutkowski, P. L., Robert, C., Gogas, H. J., Kefford, R. F., Eggermont, A. M. M., Martín‐Algarra, S., Hauschild, A., et al. (2014) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31829e885c · Cited by 13
Self-citation
Targeting PD-L1 for Non-Small-Cell Lung Cancer
Feld, E., & Horn, L. (2016) · Immunotherapy · doi:10.2217/imt-2016-0012 · Cited by 14
Immunotherapy of advanced renal cell carcinoma: Current and future therapies
Gill, D. M., Hahn, A. W., Sonpavde, G., & Agarwal, N. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1212794 · Cited by 13
Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios
Tay, R. Y., Prelaj, A., & Califano, R. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.80 · Cited by 13
“While most irAEs have a median time to onset of 6–12 weeks after initiation of therapy (15,16), onset of first irAE has been documented as late as 12 months after treatment discontinuation (7).”
Background
A review of the imaging manifestations of immune check point inhibitor toxicities
Thomas, R., Sebastian, B., George, T., Majeed, N. F., Akinola, T., Laferriere, S. L., & Braschi‐Amirfarzan, M. (2020) · Clinical Imaging · doi:10.1016/j.clinimag.2020.04.007 · Cited by 13
COVID‐19, varying genetic resistance to viral disease and immune tolerance checkpoints
Goodnow, C. C. (2020) · Immunology and Cell Biology · doi:10.1111/imcb.12419 · Cited by 15
Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade: A Case Report
Matull, J., Livingstone, E., Wetter, A., Zimmer, L., Zaremba, A., Lahner, H., Schadendorf, D., & Ugurel, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.592609 · Cited by 14
“A pooled analysis of patients treated with ipilimumab (10 mg/kg Q3W) showed a characteristic pattern in the timing of the occurrence of distinct irAEs (11).”
The state of therapy modalities in clinic for biliary tract cancer
Chen, W., Hu, Z., Song, J., Wu, Y. C., Zhang, B., & Zhang, L. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2706185 · Cited by 13
“Immune-mediated hepatitis occurs in 3– 9% of patients treated with CTLA4 inhibitors (ipilimumab) and 1–4% of patients with PD-1 inhibitors (nivolumab) [159,160].”
Background
Tremelimumab-Associated Tumor Regression Following After Initial Progression: Two Case Reports
Shimomura, A., Fujiwara, Y., Kondo, S., Kodaira, M., Iwasa, S., Kitano, S., Tanabe, Y., Tamura, K., & Yamamoto, N. (2015) · Immunotherapy · doi:10.2217/imt.15.89 · Cited by 13
Cardio-Oncology: mechanisms of cardiovascular toxicity
Markman, T. M., & Markman, M. (2018) · F1000Research · doi:10.12688/f1000research.12598.1 · Cited by 13
Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy
Dumbrava, E. I., Smith, V., Alfattal, R., El‐Naggar, A. K., Peñas-Prado, M., & Tsimberidou, A. M. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000224 · Cited by 13
Roles of intestinal microbiota in response to cancer immunotherapy
Cong, J., & Zhang, X. (2018) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-018-3374-8 · Cited by 13
Harnessing Immune Checkpoints for Cancer Therapy
Vinay, D. S., & Kwon, B. S. (2018) · Immunotherapy · doi:10.2217/imt-2017-0168 · Cited by 14
Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon
Helmink, B. A., Roland, C. L., Kiernan, C. M., & Wargo, J. A. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-019-08183-0 · Cited by 13
“3).(9) Renal toxicity from anti-CTLA4 therapy most often occurs 2 to 3 months after therapy, whereas renal toxicity resulting from anti-PD-1 therapy occurs 3 to 10 months after therapy (Fig.”
Background
Clinical characteristics of adrenal insufficiency as an immune-related adverse event in non-small-cell lung cancer
Ida, H., Goto, Y., Sato, J., Kanda, S., Shinno, Y., Morita, R., Murakami, S., Matsumoto, Y., Yoshida, T., Horinouchi, H., et al. (2020) · Medical Oncology · doi:10.1007/s12032-020-01357-x · Cited by 13
Hypohidrosis as an Immune-Related Adverse Event of Checkpoint Inhibitor Therapy
Kersh, A. E., Schuchter, L. M., Elenitsas, R., & Chu, E. Y. (2020) · Immunotherapy · doi:10.2217/imt-2020-0002 · Cited by 13
Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities
Boussios, S., Sheriff, M., Rassy, E., Moschetta, M., Samartzis, E. P., Hallit, R., Sadauskaite, A., Katsanos, K. H., Christodoulou, D. K., & Pavlidis, N. A. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-7361 · Cited by 12
“Gastrointestinal manifestations occurred usually 5 to 10 weeks after treatment onset, and typically included diarrhea and colitis (60).”
Background
Doubling the blockade for melanoma immunotherapy
Galluzzi, L., Eggermont, A. M. M., & Kroemer, G. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1106127 · Cited by 13
Diagnostic Challenges in Enteropathies: A Histopathological Review
Enache, I., Nedelcu, I. C., Balaban, M., Balaban, D. V., Popp, A., & Jinga, M. (2025) · Diagnostics · doi:10.3390/diagnostics15121511 · Cited by 12
“Notably, there is a reported case of ipilimumab inducing severe new-onset celiac disease (CD), suggesting that it may unmask latent CD [115,116].”
Controversies in the Management of Advanced Melanoma
Jarkowski, A., Norris, L. B., & Trinh, V. A. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014544165 · Cited by 12
CANCER IMMUNOTHERAPY BASED ON THE BLOCKADE OF IMMUNE CHECKPOINTS
Васильевна, Б. А., Efimov, G. A., Drutskaya, M. S., & Недоспасов, С. А. (2015) · Medical Immunology (Russia) · doi:10.15789/1563-0625-2015-5-395-406 · Cited by 12
Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology
Gridelli, C., Ascierto, P. A., Barberis, M. C. P., Felip, E., Garon, E. B., O'Brien, M. E. R., Senan, S., Casaluce, F., Sgambato, A., Papadimitrakopoulou, V., et al. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1234602 · Cited by 12
Rational design and identification of immuno-oncology drug combinations
Iafolla, M. A. J., Selby, H. M., Warner, K., Ohashi, P. S., Haibe‐Kains, B., & Siu, L. L. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.02.027 · Cited by 12
Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report
Randhawa, M., Gaughran, G., Archer, C., Pavli, P., Morey, A. L., Ali, S. S., & Yip, D. (2019) · World Journal of Clinical Oncology · doi:10.5306/wjco.v10.i10.350 · Cited by 12
The role of T cell trafficking in CTLA-4 blockade-induced gut immunopathology
Zhang, S., Liang, W., Luo, L., Sun, S., & Wang, F. (2020) · BMC Biology · doi:10.1186/s12915-020-00765-9 · Cited by 12
Febrile neutropenia in a patient with non-small-cell lung cancer treated with atezolizumab: A case report
Seguchi, K., Nakashima, K., Terao, T., Takeshita, G., Nagai, T., & Tanaka, Y. (2021) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2021.101439 · Cited by 12
“From a pharmacological perspective, dose adjustment for readministration of ICIs is not recommended because irAEs related to anti-PD1 or anti-PD-L1 are not dose-dependent [11].”
Background
Predictive Biomarkers of Severe Immune-Related Adverse Events With Immune Checkpoint Inhibitors: Prevention, Underlying Causes, Intensity, and Consequences
Cardeña-Gutiérrez, A., & Barahona, M. L. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.908752 · Cited by 12
“Furthermore, a few attempts were made at administering preventive treatment for the irAEs, which have been unsuccessful (65).”
Background
Ipilimumab in the Treatment of Prostate Cancer
Reese, Z. L., Straubhar, A., Pal, S. K., & Agarwal, N. (2015) · Future Oncology · doi:10.2217/fon.14.196 · Cited by 13
Immune Checkpoint Inhibitors in Melanoma
Cooper, A. J., Carlino, M. S., & Kefford, R. F. (2015) · Melanoma Management · doi:10.2217/mmt.15.17 · Cited by 12
Current State of Immune-Based Therapies for Glioblastoma
Lim, M. K., Weller, M., & Chiocca, E. A. (2016) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbk_159084 · Cited by 16
“Treatments often require stopping the treatment, starting high-dose corticosteroids, and possibly administering infliximab.(12,13,23)”
Background
How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know
Davies, M. J. (2016) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2016.7.5.3 · Cited by 12
“Data have suggested an improved response in patients who have higher PD-L1 expression.”
Influential
Improved Antitumor Activity of a Therapeutic Melanoma Vaccine through the Use of the Dual COX-2/5-LO Inhibitor Licofelone
Neumann, S., Shirley, S. A., Kemp, R. A., & Hook, S. M. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00537 · Cited by 13
“However utilizing a safe, small molecule drug such as licofelone to reduce tumor-induced immune suppression and potentiate immune responses stimulated by therapeutic vaccines provides an attractive alternative to the use of checkpoint blockade inhibitors; which while proving to be very effective in some situations (52…”
Background
Immune activation effects of Eurotium cristatum on T cells through NF-κB signaling pathways in humans
Yan, Z., Lin, P., Kook, M., Yi, T., & Li, C. (2017) · Food and Agricultural Immunology · doi:10.1080/09540105.2017.1293012 · Cited by 12
Systemic Therapy Options for Patients With Unresectable Melanoma
Yushak, M. L., Chapman, P. B., Robert, C., & Kudchadkar, R. R. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_174934 · Cited by 12
Immunotherapy: The Wave of the Future in Bladder Cancer?
Petrylak, D. P. (2017) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2017.05.025 · Cited by 12
“major categories of irAEs associated with ipilimumab and the characteristic patterns in the timing of their occurrence.(26) Across tumor types, common irAEs include dermatologic effects, consti-”
Background
Long-term and late treatment consequences: endocrine and metabolic effects
Han, T. S., & Gleeson, H. K. (2017) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000289 · Cited by 11
Toxicity of Checkpoint Inhibition in Advanced RCC: A Systematic Review
Ornstein, M. C., & Garcia, J. A. (2017) · Kidney Cancer · doi:10.3233/kca-170017 · Cited by 12
“Most clinical trials and pooled analyses of CPIbased therapy suggest these events occur anywhere from weeks to years after the initiation of therapy and even after therapy cessation [24, 32].”
Background
Resolution of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) during Nivolumab therapy for non-small cell lung cancer: a case report.
Filetti, M., Anselmi, E., Macrini, S., Rizzo, F., Iacono, D., Giusti, R., & Marchetti, P. (2018) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2017.12.013 · Cited by 12
Top Ten Tips for Palliative Care Clinicians Caring for Cancer Patients Receiving Immunotherapies
Wiesenthal, A. C., Patel, S. P., LeBlanc, T. W., Roeland, E. J., & Kamal, A. H. (2018) · Journal of Palliative Medicine · doi:10.1089/jpm.2018.0107 · Cited by 12
“In coordination with the oncology team, when patients experience grade 2 or 3 irAEs, general recommendations as discussed above are to start oral prednisone 1 to 2 mg/kg/day or dexamethasone 4 mg every four hours, followed by a taper over the next four weeks.(8) Severe immune-related side effects (e.”
Immunotherapy in Gliomas
Weant, M. P., Jesús, C. M.-D., & Yerram, P. (2018) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2018.10.011 · Cited by 12
Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis
Hou, Y., Wang, D., Hu, J., Tian, R., Wang, W., Su, Q., Li, H., & Wang, Y. (2021) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2021.1890133 · Cited by 12
“IrAEs were not frequently observed in chemotherapy.(52) Traditional chemotherapy agents involved mostly in our study include taxane (Docetaxel, Paclitaxel) and platinum (Cisplatin).”
Background
Side-effects of Modern Immunotherapy and How to Solve Th em in the Clinics
Lakomý, R., & Poprach, A. (2015) · Klinicka onkologie · doi:10.14735/amko20154s103 · Cited by 12
Organ-specific accuracy of [18F]FDG-PET/CT in identifying immune-related adverse events in patients with high-risk melanoma treated with adjuvant immune checkpoint inhibitor
Gideonse, B. M., Birkeland, M., Vilstrup, M. H., Grupe, P., Naghavi‐Behzad, M., Ruhlmann, C. H. B., Gerke, O., & Hildebrandt, M. G. (2024) · Japanese Journal of Radiology · doi:10.1007/s11604-024-01554-y · Cited by 12
“Early detection and identification of irAEs and prompt treatment initiation can improve clinical outcomes and lower the risk of sequelae [9, 10].”
Background
Risk Factors for Immune Checkpoint Inhibitor-Induced Liver Injury and the Significance of Liver Biopsy
Kawano, M., Yano, Y., Yamamoto, A., Yasutomi, E., Inoue, Y., Kitadai, J., Yoshida, R., Matsuura, T., Shiomi, Y., Ueda, Y., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14080815 · Cited by 13
Multidisciplinary management of immunotherapy‐related adverse events in solid tumors: An inter‐institutional and telemedicine‐based working team
Iaculli, A., Ghidini, M., Locati, F., Chiappa, L., Nastasi, G., Fasola, G., Grossi, F., Garrone, O., & Tozzi, V. D. (2024) · Cancer Medicine · doi:10.1002/cam4.7403 · Cited by 11
Endoscopic findings of immune checkpoint inhibitor-related gastrointestinal adverse events
Kim, M. K., & Hwang, S. W. (2024) · Clinical Endoscopy · doi:10.5946/ce.2024.003 · Cited by 11
“Although the median onset typically occurs six to eight weeks after initiating anti-CTLA-4 therapy 8 and two to six months following anti-PD-1/anti-PD-L1, 9,10 the onset times can vary.”
Background
Phase I/II RAF kinase inhibitors in cancer therapy
Turajlic, S., Ali, Z., Yousaf, N., & Larkin, J. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.797964 · Cited by 11
Challenging Cases: Management of Immune-Related Toxicity
Weber, J. S. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_209557 · Cited by 10
Self-citation
Enhanced anti-tumor immunity of vaccine combined with anti-PD-1 antibody in a murine bladder cancer model
Lim, S., Park, J.-H., & Chang, H. K. (2022) · Korean journal of urology · doi:10.4111/icu.20220031 · Cited by 11
“Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) inhibits T-cell activation at the initial activation site; therefore, several clinical studies using anti-CTLA-4 antibodies have been conducted in various types of cancer patients with or without chemotherapy [6,7].”

Authors: Weber, J. S., Kähler, K. C., & Hauschild, A.
Affiliations: Moffitt Cancer Center (US)
ORCID: Weber, Jeffrey S.
Kähler, Katharina C.
Hauschild, Axel
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2012-07-20
Volume: 30
Issue: 21
Pages: 2691-2697
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2012.41.6750
OpenAlex: W2109653150
Cited by: 1,415
References: 33
Citations by year: 2026: 24 · 2025: 35 · 2024: 59 · 2023: 79 · 2022: 84 · 2021: 117 · 2020: 129 · 2019: 123 · 2018: 146 · 2017: 153 · 2016: 152 · 2015: 145 · 2014: 94 · 2013: 65 · 2012: 9
FWCI: 10.34
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords: ipilimumab, immune-related adverse events, CTLA-4 blockade, metastatic melanoma, immune checkpoint inhibitors, toxic epidermal necrolysis, colitis, hypophysitis, hepatitis, iridocyclitis, neuropathy, nephritis, adverse event management
MeSH terms: Ipilimumab, Antibodies, Monoclonal, Antineoplastic Agents, Colitis, Drug Eruptions, Diarrhea, Humans, Liver, Lymphatic Diseases, Melanoma, Mucous Membrane, Pancreatitis, Peripheral Nervous System Diseases, Pituitary Gland, Skin, Skin Neoplasms, Stevens-Johnson Syndrome, Uveitis, Scleritis, Chemical and Drug Induced Liver Injury, CTLA-4 Antigen, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks